Wat is de prijs voor Pascal Biosciences Inc. (PSCBF)

Het prijs van Pascal Biosciences Inc. (PSCBF) is $0.1

Wat is de marktkapitalisatie voor Pascal Biosciences Inc. (PSCBF)

Marktkapitalisatie voorPascal Biosciences Inc. (PSCBF) is $1.31M

Pascal Biosciences Inc. (PSCBF) Uitstaande Aandelen

Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for oncology and bolstering immune system function. The company's robust pipeline includes several key candidates: PAS-403, a potent mitosis inhibitor designed to impede cancerous cell division, specifically targeting glioblastoma and secondary brain tumors; and PAS-393, an immunomodulatory cannabinoid developed to enhance the immune system's recognition of tumor cells when utilized alongside checkpoint inhibitor therapy. Furthermore, Pascal is progressing a specialized antibody therapy aimed at B-cells, intended for conditions like acute lymphoblastic leukemia and various B-cell lymphomas. The company is also investigating cannabinoid-derived products as potential treatments for COVID-19. To support its research, Pascal Biosciences maintains an exclusive licensing agreement with the University of Washington for a cannabinoid-based therapeutic against glioblastoma multiforme and brain metastases. It also benefits from a collaborative research partnership with SoRSE Technology Corporation, focused on advancing PAS-393 toward clinical trials. Founded in 2011, the company operates from its headquarters in Seattle, Washington.

Jaar	Uitstaande aandelen	Wijzigen
2026 (TTM)	38.14M	62.10%
2023	23.53M	79.48%
2022	13.11M	3.25%
2021	12.70M	14.59%
2020	11.08M	5.23%
2019	10.53M	0.00%

Jaar

Uitstaande aandelen

Wijzigen

2026 (TTM)

38.14M

62.10%

2023

23.53M

79.48%

2022

13.11M

3.25%

2021

12.70M

14.59%

2020

11.08M

5.23%

2019

10.53M

0.00%

Bedrijf	Uitstaande aandelen	Verschil	Land
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	565.70%	US
Argenx SE ARGX.US	62.19M	63.04%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	0.00	-100.00%	BE

Bedrijf

Uitstaande aandelen

Verschil

Land